Guidance, NICE advice and quality standards in development | Guidance

Showing 291 to 300 of 379

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6454]	Technology appraisal guidance	TBC
Satralizumab for treating relapsing myelin oligodendrocyte glycoprotein antibody associated disease [TSID12420]	Technology appraisal guidance	TBC
Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520]	Technology appraisal guidance	TBC
School-based interventions: physical and mental health and wellbeing promotion	Quality standard	TBC
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]	Technology appraisal guidance	TBC
Secukinumab for treating giant cell arteritis in people 50 years and over [ID6563]	Technology appraisal guidance	TBC
Secukinumab for treating relapsed polymyalgia rheumatica ID6599	Technology appraisal guidance	TBC
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]	Technology appraisal guidance	TBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]	Technology appraisal guidance	TBC
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385]	Technology appraisal guidance	TBC